linjc16/ctgov huggingface dataset:
The Comparison of Anterior Knee Pain in Patella With or Without Denervation in Medial Unicompartmental Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
the present study will conduct to assess anterior knee pain and complications after medial UKA with or without patella denervation in medial compartment arthritis and severe lateral facet patellofemoral arthritis patients.

Detailed Description
-----------------
In this prospective cohort study, the investigators will conduct to compare the clinical result of 70 patients of unicompartment knee arthroplasty with and without patella denervation between April, 2018 and April, 2019 for the patients with osteoarthritis.

Official Title
-----------------
The Comparison of Anterior Knee Pain in Patella With or Without Denervation in Medial Unicompartmental Knee Arthroplasty

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Procedure: patella denervation
* Procedure: patella non-denervation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who diagnose with medial osteoarthritis (OA) of the knee with an Alhback score of 2, 3 and 4 (Ahlback 1968) and with any Kujala score for pre-operative anterior knee pain. Older than 40 years of age. pain on the medial joint line. primary medial compartment osteoarthritis with a well preserved lateral compartment with competent cruciate ligaments with correctable intraarticular varus deformity. ROM flexion up to 110° under anesthesia. Exclusion Criteria: Patients with fixed varus deformity > 15° Inflammatory arthritis Previous high tibial osteotomy or ACL reconstruction

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: unicompartment knee arthroplasty with patella denervation
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: unicompartment knee arthroplasty and patella denervation<br>UKA and patella denervation | Procedure: patella denervation<br>* patella denervation<br>|
| Experimental: unicompartment knee arthroplasty and patella non-denervation<br>UKA and patella non-denervation | Procedure: patella non-denervation<br>* patella non-denervation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kujala score | Kujala score including 13 parameters with the score of 0-100, the higher the score the better the function. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication | number of participant with DVT, infections, loosening of implants, fractures, lateral compartment arthritis, and dislocations of the polyethylene | 6 months |
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.

Official Title
-----------------
An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece

Conditions
-----------------
Type 2 Diabetes Mellitus, CV Risk

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients with diabetes type 2 that their physician has decided to prescribe AVANDIA for better control of their condition Have signed informed consent Exclusion Criteria: Patients with ALT > 2.5x the normal value With heart failure symptoms With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates With recent myocardial infarction (<6 months) With severe renal disfunction Pregnant or lactating or planned to be pregnant during the study Under investigational drug treatment Alcoholic or drug abuser

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes, CV risk, rosiglitazone, AVANDIA
Utility of Disconnection Technique for One Lung Ventilation

Study Overview
=================
Brief Summary
-----------------
Lung isolation technique is useful for lung or heart surgeries for better visualization. Double lumen endobronchial tube and bronchial blocker are available for lung isolation. Adding disconnection technique before lung isolation is helpful to accelerate the lung deflation. However, the utility of disconnection technique has never been evaluated in comparison of double lumen tube and bronchial blocker. Therefore, the utility of disconnection technique in two different lung isolation technique, double lumen tube and bronchial blocker will be evaluated

Official Title
-----------------
Utility of Disconnection Technique for One Lung Ventilation: a Comparison of a Double Lumen Endobronchial Tube With a Bronchial Blocker

Conditions
-----------------
Pneumothorax

Intervention / Treatment
-----------------
* Other: disconnection technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for wedge resection for pneumothorax, unilateral ASA class I, II Exclusion Criteria: know lung disease any kind of lung abnormality on preoperative chest x-ray coronary artery occlusive disease cerebrovascular disease pregnancy unable to understand the informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DLT(Double Lumen Tube) group<br>disconnection technique will be applied | Other: disconnection technique<br>* Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.<br>|
| Experimental: BB(Bronchial Blocker) group<br>disconnection technique will be applied | Other: disconnection technique<br>* Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung deflation score | verbal analog scale(0=no deflation, 10=complete deflation) | 10 min after inflation of balloon | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time for initial placement |  | from beginning of intubation until confirmation of adequate placement with bronchoscope, approximately 5 minute | 
| time for lung deflation |  | from turning the ventilator off until the carbon dioxide reach to zero on capnography, within 2 min |
Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction

Study Overview
=================
Brief Summary
-----------------
The present study aimed to evaluate the effect of rosiglitazone treatment on cardiac function compared with metformin

Detailed Description
-----------------
Large scale clinical trials have reported fluid retention and increase in plasma volume (6% to 7%) with glitazone therapy, with an increased incidence of peripheral edema occuring in 2% to 5% patients. Some evidence suggests that this effect may be related to increased endothelial cell permeability induced by glitazones therapy. Others report that glitazones may interfere with renal hemodynamics. In controlled clinical trials, the frequency of new onset congestive heart failure was very low in glitazones treated patients. The incidence of congestive heart failure is higher in patients receiving combination therapy with insulin and glitazones. Only few studies compared rosiglitazone and metformin on cardiac safety. Recently a study reported a reversible increase in endothelial cell permeability to albumin in cultured pulmonary arterial cells treated with rosiglitazone. To our knowledge, there is not any clinical study published for showing the reversibility of the cardiac adverse effects if the rosiglitazone treatment is continued.

Official Title
-----------------
A Study of PPAR-Gamma Agonist-Rosiglitazone for Determining Cardiac Adverse Effects in Type 2 Diabetic Patients

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: Rosiglitazone(drug), cardiac adverse effects


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes mellitus treated with oral hypoglycemic agents or diet only Without any symptom or finding of heart failure Normal liver enzymes and renal functions Exclusion Criteria: Any known coronary artery disease, congestive hearth failure, renal disease or liver disease Any treatment for heart failure or diuretics for any reasons.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rosiglitazone(drug), cardiac adverse effects|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma Brain Natriuretic Peptide levels, echocardiographic measurements were made before the treatment and repeated after three months and six months of the treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Natriuretic Peptide, Brain, Heart Failure, Congestive
Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence

Study Overview
=================
Brief Summary
-----------------
Randomized controlled trial (RCT) to evaluate the effectiveness of applying Purell® (62% ethyl alcohol in emollient gel) to the penis of male partners of women diagnosed with BV for preventing BV recurrence after treatment.

Official Title
-----------------
Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence

Conditions
-----------------
Bacterial Vaginosis

Intervention / Treatment
-----------------
* Other: hygienic information plus 62% ethyl alcohol in emollient gel
* Other: hygienic information


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Vaginal symptoms Nugent score > 6 for vaginal fluid gram stain Woman and her male partner both interested in study participation Woman able to return for follow-up visits Woman able to provide detailed contact information for tracing Exclusion Criteria: Either male or female partner not recruited within 24 hours of the other

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Other: hygienic information plus 62% ethyl alcohol in emollient gel<br>* The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).<br>* Other names: Purell® (GOJO Healthcare Inc., Akron, OH);|
| Active Comparator: 2<br> | Other: hygienic information<br>* Couples received a brochure with information on control of STI and good hygienic practices.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacterial vaginosis by Nugent's score |  | up to 2 months following treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| presence of lactobacillus by culture |  | 2 months following treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bacterial vaginosis, recurrence, male factor
Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)

Study Overview
=================
Brief Summary
-----------------
Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.

Official Title
-----------------
Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Genetic: Protein expression by immunohistochemistry and immunofluorescence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Radically resected non small cell lung cancer patients with tumor tissue available Exclusion Criteria: Tumor tissue not available Clinical data not available

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Radically resected Non small cell lung cancer patients in stage I-III | Genetic: Protein expression by immunohistochemistry and immunofluorescence<br>* Protein expression by immunohistochemistry and immunofluorescence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of different biomarkers with survival |  | At the end of enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of a specific biomarker with patient's characteristics |  | At the end of enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non small cell lung cancer patients
Prevalence of IL28B Polymorphism in Hepatitis C Patients

Study Overview
=================
Brief Summary
-----------------
Response to peginterferon and ribavirin treatment in hepatitis C (HCV) depends on viral and host factors. Single nucleotide polypmorphisms (SNP) near to IL28B gene (especially at rs12979860 and rs8099917) are strongly associated with the response to treatment in HCV genotype 1 infection, less so in HCV genotype 2/3 infection. CC genotype in rs12979860 and TT genotype at rs8099917 are associated with good treatment outcome. Asian populations have high prevalence of CC genotype in other studies, which can explain relatively good response to peginterferon/ ribavirin in genotype 1 infection in Asians compared with Caucasians.

Detailed Description
-----------------
The prevalence of different genotypes of IL28B polymorphism in the local population will be studied. DNA will be extracted from the whole blood sample of hepatitis C patients with genotype 1, 2 and 3 infection. It will be amplified by real-time PCR and subsequently analysed for the genotypes of IL28B SNPs.

Official Title
-----------------
Prevalence of IL28B Polymorphism in Hepatitis C Patients in Singapore and Its Effect on the Outcome of Hepatitis C Treatment

Conditions
-----------------
Hepatitis C

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with positive HCV IgG (EIA or RIBA test) and positive HCV RNA test (RT-PCR) HCV genotypes 1, 2 or 3 (determined by Versant™ HCV genotype Assay LiPA 2.0) with or without HCV treatment (peginterferon/ ribavirin). Exclusion Criteria: -Patients with acute hepatitis C infection.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HCV genotype 1 and genotype 2/3<br>DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the prevalence of genetic variants for IL28B SNPs (rs 12979860 and rs 8099917) in HCV patients in Singapore. |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The distribution of the different SNP variants in different ethnic groups (Chinese, Malay, Indian and others) |  | Baseline | 
| The association of the genetic variants and the treatment response in patients receiving peg-interferon/ ribavirin therapy. | To study the correlation between genetic variants and treatment response | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IL28B gene
Microcurrent Stimulation to Treat Macular Degeneration

Study Overview
=================
Brief Summary
-----------------
Microcurrent stimulation thereapy improves retinal efficiency and may restore and/or improve retinal function.

Detailed Description
-----------------
This is an observational study in which data will be collected from a group of patients with retinal diseases such as Dry Macular Degeneration, RetinitisPigmentosa, and Stargardt's Disease, who have opted to receive Microcurrent Stimulation Therapy as an alternative treatment for their retinal condition.

Official Title
-----------------
An Observational, Multi-Center Phase 1 Study of the Safety and Effectiveness of Frequency Specific Microcurrent Stimulation as an Alternative Treatment for Retinal Diseases

Conditions
-----------------
Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide written consent and comply with follow up visits Age 40 years or older ETDRS best corrected visual acuity better than 5 letters History of Dry Age Relted Macular Degeneration; Retinitis Pigmentosa; Stargardt's disease No Anti-VEGF treatments for at least 3 months prior to study No new antioxidant/vitamin supplementation for at least 3 months prior to study Exclusion Criteria: History of Non-Compliance with regular medical visits Significant media opacities (exclude NS 4+) that may interfere with assessing visual acuity Presence of pigment epithelial tears or rips Known serious allergies to fluorescein dye Presence of retinal neovascularization Any treatment with an investigation agent in the past 30 days

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure visual acuity after receiving microcurrent stimulation treatments. |  | 6 months |
Natural History Study for Achromatopsia

Study Overview
=================
Brief Summary
-----------------
In preparation for human clinical trials we intend to undertake a detailed phenotypic study to help to identify patients who may be suitable for therapeutic intervention. In addition, with the recent availability of advanced imaging modalities, further detailed phenotypic investigations will also be valuable in helping to probe the relationship between structure and function and may shed light on disease mechanisms.

Official Title
-----------------
Phenotyping and Genotyping Patients With Achromatopsia in Preparation for Gene Therapy Trials

Conditions
-----------------
Achromatopsia

Intervention / Treatment
-----------------
* Diagnostic Test: Ocular assessments


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with molecularly proven Achromatopsia or a typical clinical Achromatopsia phenotype with genetic screening pending. Minimum subject age of 3 years. Able to give consent/parent or guardian able to give consent. Exclusion Criteria: Patients unable or unwilling to undertake consent or clinical testing. Patients unwilling to donate a blood sample in order to establish the genetic cause of their condition.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Achromatopsia<br> | Diagnostic Test: Ocular assessments<br>* Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete ocular examination |  | 5 years | 
| Axial length |  | 5 years | 
| Corneal curvature |  | 5 years | 
| Optical Coherence Tomography |  | 5 years | 
| Visual acuity |  | 5 years | 
| Contrast sensitivity |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Achromatopsia, CNGB3, CNGA3